Boan Biotech’s Boyoujing^® Approved for Marketing in China for the Treatment of nAMD and DME

Boan Biotech today announced that its aflibercept intravitreous injection Boyoujing® has been approved by China’s National Medical Products Administration (NMPA) for the treatment of neovascular...

VOLUNTARY ANNOUNCEMENT BOYOUJING (AFLIBERCEPT INTRAVITREOUS INJECTION) APPROVED FOR MARKETING IN CHINA

Marketing Authorization Applications for Boan Biotech’s Two Denosumab Injections Accepted in the UK

Yantai, China, October 7, 2025 – Boan Biotech today announced that the Marketing Authorization Applications (MAAs) for its two denosumab injections, BA6101, a 60 mg denosumab injection for ortho...

VOLUNTARY ANNOUNCEMENT MARKETING AUTHORISATION APPLICATIONS FOR THE COMPANY'S TWO DENOSUMAB INJECTIONS ACCEPTED IN THE UK

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2025

BA1104 Phase III Trial in China Completes Patient Enrollment

Boan Biotech today announced that all the patients have been enrolled in a Phase III clinical trial of its nivolumab injection code-named BA1104 in China. This is China’s first biosimilar of Opd...

VOLUNTARY ANNOUNCEMENT THE ENROLLMENT FOR PHASE III TRIAL OF THE COMPANY'S NIVOLUMAB INJECTION HAS BEEN COMPLETED IN CHINA

Boan Biotech Presents Early Findings about BA1301 at ESMO 2025

Boan Biotech today announced that the preliminary results of the ongoing Phase I clinical study for its BA1301, an investigational antibody-drug conjugate (ADC), were recently presented at the 2025 Co...

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2025

Articles of Association